Canadian ophthalmic technology company Ocumetics Technology Corp has announced that it is undertaking what it claims is the first-in-human (FIH) clinical studies of its “revolutionary” accommodating intraocular lens.
“This moment is nothing short of transformational,” said Mr Dean Burns, CEO of Ocumetics, in a media release.
“With clinical study site initiation set to begin this week (June 26), we are now taking the most significant step yet in bringing the Ocumetics lens to market.
“What began as a dream to restore the youthful eye’s natural ability to focus on distant and near objects after cataract surgery is one step closer to becoming a reality. With a world-class team, innovative technology, and unwavering determination, we are redefining what’s possible in ophthalmology.”
The release said the work marked a “groundbreaking leap into the future of vision correction” for Ocumetics as it initiates pivotal clinical trials of its accommodating intraocular lens – “an implantable device that promises to provide patients worldwide with youthful, dynamic vision after cataract surgery”.
The company said it had made impressive strides leading to this pivotal moment:
- Lens design freeze: Final lens specifications are locked in, marking a major milestone in the journey from design and development to commercialisation.
- Manufacturing completed: Ocumetics successfully produced its first batch of lenses to be used for the upcoming FIH implantations.
- Laboratory testing: Lab bench testing confirmed that the Ocumetics lens provides sufficient accommodative power to restore a patient’s ability to focus on both distance and near objects without glasses.
- Mexico City selected as trial site: Following an extensive review of available options, Mexico City was chosen as the first clinical trial site because of its strong infrastructure and experienced investigators.
- Clinical protocol finalised and submitted: The protocol for a pivotal clinical study planned for this summer has been submitted to regulatory agencies.
- Funding: Ocumetics announced a private placement of up to CAD$2.1 million, led by Numus Capital, to fund its clinical study, as well as ongoing research and development activities.
Dr Garth Webb, founder and chief scientific officer of Ocumetics, commented: “This is the culmination of years of tireless innovation. The Ocumetics lens is not just a product; it represents a potential paradigm shift in vision restoration. We’re proud to be leading this next chapter in ophthalmic science.”
More reading
UK trials consultation, bilateral cataract surgery on one day, and no eye drops
Performing cataract surgery … sustainably
Major Aussie study: Surgeons in public sector seeing more complex cataract cases
